| http://www.w3.org/ns/prov#value | - By 1992, the FDA had codified new regulations for accelerated approval for new drugs to treat AIDS and other life-threatening diseases, by allowing drugs to be approved based on beneficial changes in surrogate markers, such as CD4 cell counts or later viral load levels, which were thought to predict clinical benefit.
|
